Angeles Alvarez Secord | Scholars@Duke

Angeles Alvarez Secord
Professor of Obstetrics and Gynecology

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Current Appointments & Affiliations

Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2013
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1994

Contact Information

25172 Morris Bldg, Durham, NC 27710
Box 3079 Med Ctr, Durham, NC 27710
secor002@mc.duke.edu (919) 684-3765

Background
Education, Training, & Certifications
- Resident, Obstetrics & Gynecology, Duke University 1994 - 1998
- M.D., University of Washington 1994
Duke Appointment History
- Associate Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2009 - 2013
- Associate Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2007 - 2009
- Assistant Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2002 - 2007
- Associate in the Department of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 1998 - 2002
Research
Selected Grants
- SGNTV-002: Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen awarded by Seattle Genetics, Inc 2019 - 2024
- A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician¿s Choice in Participants with Adva awarded by Merck Sharp & Dohme 2018 - 2023
- Atezo NACT for Ovarian Cancer awarded by Genentech, Inc. 2017 - 2022
- GOG 3018: OVAL awarded by Gynecologic Oncology Group 2019 - 2022
- GOG 3025: DUO-O awarded by Gynecologic Oncology Group 2019 - 2022
- GOG 3020: ATHENA awarded by Gynecologic Oncology Group 2019 - 2022
- Atezo NACT for Ovarian Cancer (Bio- Markers Lab Clinc Resch) awarded by Genentech, Inc. 2018 - 2022
- GOG3015 Foundation Study ( Atezo Frontline) awarded by Genentech, Inc. 2018 - 2021
- Phase 2 Trial of Dose Dense (Weekly) Paclitaxel with Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer awarded by H. Lee Moffitt Cancer Center & Research Institute 2016 - 2021
- Tapimmune FRV-004 awarded by Tapimmune, Inc. 2018 - 2021
- GOG3005-ABB VIE Protocol M13-694 awarded by Gynecologic Oncology Group 2015 - 2020
- CORAIL awarded by PharmaMar USA, Inc. 2015 - 2020
- A Phase 2 Randomized Double-Blind Trial of Maintenance with Niraparib vs Placebo awarded by TESARO 2013 - 2019
- A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Cancers of Muellerian Origin awarded by Merck Sharp & Dohme 2016 - 2019
- NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER awarded by NRG Oncology 2017 - 2019
- Quadra Study awarded by TESARO 2015 - 2019
- NCI National Clinical Trials Network U10 (Year 5) awarded by National Institutes of Health 2014 - 2019
- Women with BRCA-mutated Advanced Stage Ovarian Cancer awarded by AstraZeneca LP 2017 - 2019
- GOG3016 Foundation Study ( Atezo Frontline) awarded by Regeneron Pharmaceuticals, Inc. 2018
- Apera ARP-407 awarded by Aprea Therapeutics 2017 - 2018
- Lynparza Open Acess Olaparib awarded by AstraZeneca AB 2017 - 2018
- Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer awarded by American Association of Obstetricians and Gynecologists Foundation 2017 - 2018
- Assessing the relevance of weighted values in the ASCO value framework in ovarian cancer patients awarded by Gynecologic Oncology Group 2016 - 2017
- Blood-based Angiome Profiling to Direct Bevacizumab Therapy in Ovarian Cancer awarded by National Institutes of Health 2014 - 2017
- Tesaro Ovarian Cancer Practicum awarded by TESARO 2016
- A Phase III Randomized, Double-Blind, Placebo Controlled Multicrentre Study of Olaparib Maintenance Monotherapy awarded by AstraZeneca Pharmaceuticals, LP 2014 - 2015
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Moore, K, Chan, JK, Secord, AA, Patel, MR, Callahan, T, Guo, W, and Zhang, Z-Y. "Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.(Accepted)" Cancer Chemotherapy and Pharmacology 83, no. 4 (April 2019): 717-726. Full Text
  - Foote, JR, Secord, AA, Liang, MI, Ehrisman, JA, Cohn, DE, Jewell, E, and Havrilesky, LJ. "Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer." Gynecologic Oncology 152, no. 3 (March 1, 2019): 445-451. Full Text
  - Previs, RA, and Secord, AA. "Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management." Obstetrics and Gynecology Clinics of North America 46, no. 1 (March 2019): 67-88. (Review) Full Text
  - Lim, SL, Havrilesky, LJ, Habib, AS, and Secord, AA. "Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy." Gynecologic Oncology (February 2019). Full Text
  - Rose, PG, Java, JJ, Salani, R, Geller, MA, Secord, AA, Tewari, KS, Bender, DP, Mutch, DG, Friedlander, ML, Van Le, L, Method, MW, Hamilton, CA, Lee, RB, Wenham, RM, Guntupalli, SR, Markman, M, Muggia, FM, Armstrong, DK, Bookman, MA, Burger, RA, and Copeland, LJ. "Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma." Obstetrics and Gynecology 133, no. 2 (February 2019): 245-254. Full Text
  - Puechl, AM, Edwards, J, Suri, A, Nakayama, J, Bean, S, Gehrig, P, Saks, E, Duska, L, Broadwater, G, Ehrisman, J, Horowitz, N, and Secord, AA. "The association between progesterone receptor expression and survival in women with adult granulosa cell tumors." Gynecologic Oncology (January 17, 2019). Full Text
  - Davidson, BA, Broadwater, G, Crim, A, Boccacio, R, Bixel, K, Backes, F, Previs, RA, Salinaro, J, Salani, R, Moore, K, and Secord, AA. "Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy." Gynecologic Oncology (December 14, 2018). Full Text
  - Lim, SL, Moss, HA, Secord, AA, Lee, PS, Havrilesky, LJ, and Davidson, BA. "Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis." Gynecologic Oncology 151, no. 3 (December 2018): 506-512. Full Text
  - Monk, BJ, Kauderer, JT, Moxley, KM, Bonebrake, AJ, Dewdney, SB, Secord, AA, Ueland, FR, Johnston, CM, and Aghajanian, C. "A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study." Gynecologic Oncology 151, no. 3 (December 2018): 422-427. Full Text
  - Tew, WP, Sill, MW, Walker, JL, Secord, AA, Bonebrake, AJ, Schilder, JM, Stuckey, A, Rice, L, Tewari, KS, and Aghajanian, CA. "Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study." Gynecologic Oncology 151, no. 2 (November 2018): 257-263. Full Text
  - DiSilvestro, P, and Alvarez Secord, A. "Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?." Cancer Treatment Reviews 69 (September 2018): 53-65. (Review) Full Text
  - Aghajanian, C, Filiaci, V, Dizon, DS, Carlson, JW, Powell, MA, Secord, AA, Tewari, KS, Bender, DP, O'Malley, DM, Stuckey, A, Gao, J, Dao, F, Soslow, RA, Lankes, HA, Moore, K, and Levine, DA. "A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer." Gynecologic Oncology 150, no. 2 (August 2018): 274-281. Full Text
  - Chan, JK, Brady, W, Monk, BJ, Brown, J, Shahin, MS, Rose, PG, Kim, J-H, Secord, AA, Walker, JL, and Gershenson, DM. "A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)." Gynecologic Oncology 150, no. 2 (August 2018): 247-252. Full Text
  - Fader, AN, Roque, DM, Siegel, E, Buza, N, Hui, P, Abdelghany, O, Chambers, SK, Secord, AA, Havrilesky, L, O'Malley, DM, Backes, F, Nevadunsky, N, Edraki, B, Pikaart, D, Lowery, W, ElSahwi, KS, Celano, P, Bellone, S, Azodi, M, Litkouhi, B, Ratner, E, Silasi, D-A, Schwartz, PE, and Santin, AD. "Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36, no. 20 (July 2018): 2044-2051. Full Text
  - Secord, AA, Previs, RA, and Nixon, AB. "Cabozantinib in ovarian clear cell cancers: UnMET expectations." Gynecologic Oncology 150, no. 1 (July 2018): 1-2. Full Text
  - Ricketts, CJ, De Cubas, AA, Fan, H, Smith, CC, Lang, M, Reznik, E, Bowlby, R, Gibb, EA, Akbani, R, Beroukhim, R, Bottaro, DP, Choueiri, TK, Gibbs, RA, Godwin, AK, Haake, S, Hakimi, AA, Henske, EP, Hsieh, JJ, Ho, TH, Kanchi, RS, Krishnan, B, Kwiatkowski, DJ, Lui, W, Merino, MJ, Mills, GB, Myers, J, Nickerson, ML, Reuter, VE, Schmidt, LS, Shelley, CS, Shen, H, Shuch, B, Signoretti, S, Srinivasan, R, Tamboli, P, Thomas, G, Vincent, BG, Vocke, CD, Wheeler, DA, Yang, L, Kim, WY, Robertson, AG, Caesar-Johnson, SJ, Demchok, JA, Felau, I, Kasapi, M, Ferguson, ML, Hutter, CM, Sofia, HJ, Tarnuzzer, R, Wang, Z, Zenklusen, JC, Zhang, J, Chudamani, S, Liu, J, Lolla, L, Naresh, R, Pihl, T, Sun, Q, Wan, Y, Wu, Y, Cho, J, DeFreitas, T, Frazer, S, Gehlenborg, N, Getz, G, Heiman, DI, Kim, J, Lawrence, MS, Lin, P, Meier, S, Noble, MS, Saksena, G, Voet, D, Zhang, H, Bernard, B, Chambwe, N, Dhankani, V, and Knijnenburg, T. "Erratum: The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (Cell Reports (2018) 23(1) (313–326.e5) (S2211124718304364) (10.1016/j.celrep.2018.03.075))." Cell Reports 23, no. 12 (June 19, 2018): 3698-null. Full Text
  - Davidson, BA, Ehrisman, J, Abbott, S, Harmon, Z, Secord, AA, Berchuck, A, Lee, PS, Valea, FA, Li, X, Havrilesky, LJ, and Hall, AHS. "Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer." International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists 37, no. 3 (May 2018): 252-255. Full Text
  - Matei, D, Ghamande, S, Roman, L, Alvarez Secord, A, Nemunaitis, J, Markham, MJ, Nephew, KP, Jueliger, S, Oganesian, A, Naim, S, Su, XY, Keer, H, Azab, M, and Fleming, GF. "A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 24, no. 10 (May 2018): 2285-2293. Full Text
  - Thorsson, V, Gibbs, DL, Brown, SD, Wolf, D, Bortone, DS, Ou Yang, T-H, Porta-Pardo, E, Gao, GF, Plaisier, CL, Eddy, JA, Ziv, E, Culhane, AC, Paull, EO, Sivakumar, IKA, Gentles, AJ, Malhotra, R, Farshidfar, F, Colaprico, A, Parker, JS, Mose, LE, Vo, NS, Liu, J, Liu, Y, Rader, J, Dhankani, V, Reynolds, SM, Bowlby, R, Califano, A, Cherniack, AD, Anastassiou, D, Bedognetti, D, Rao, A, Chen, K, Krasnitz, A, Hu, H, Malta, TM, Noushmehr, H, Pedamallu, CS, Bullman, S, Ojesina, AI, Lamb, A, Zhou, W, Shen, H, Choueiri, TK, Weinstein, JN, Guinney, J, Saltz, J, Holt, RA, Rabkin, CE, Cancer Genome Atlas Research Network, , Lazar, AJ, Serody, JS, Demicco, EG, Disis, ML, Vincent, BG, and Shmulevich, L. "The Immune Landscape of Cancer." Immunity 48, no. 4 (April 5, 2018): 812-830.e14. Full Text
  - Berger, AC, Korkut, A, Kanchi, RS, Hegde, AM, Lenoir, W, Liu, W, Liu, Y, Fan, H, Shen, H, Ravikumar, V, Rao, A, Schultz, A, Li, X, Sumazin, P, Williams, C, Mestdagh, P, Gunaratne, PH, Yau, C, Bowlby, R, Robertson, AG, Tiezzi, DG, Wang, C, Cherniack, AD, Godwin, AK, Kuderer, NM, Rader, JS, Zuna, RE, Sood, AK, Lazar, AJ, Ojesina, AI, Adebamowo, C, Adebamowo, SN, Baggerly, KA, Chen, T-W, Chiu, H-S, Lefever, S, Liu, L, MacKenzie, K, Orsulic, S, Roszik, J, Shelley, CS, Song, Q, Vellano, CP, Wentzensen, N, Cancer Genome Atlas Research Network, , Weinstein, JN, Mills, GB, Levine, DA, and Akbani, R. "A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers." Cancer Cell 33, no. 4 (April 2, 2018): 690-705.e9. Full Text
  - Liu, Y, Sethi, NS, Hinoue, T, Schneider, BG, Cherniack, AD, Sanchez-Vega, F, Seoane, JA, Farshidfar, F, Bowlby, R, Islam, M, Kim, J, Chatila, W, Akbani, R, Kanchi, RS, Rabkin, CS, Willis, JE, Wang, KK, McCall, SJ, Mishra, L, Ojesina, AI, Bullman, S, Pedamallu, CS, Lazar, AJ, Sakai, R, Cancer Genome Atlas Research Network, , Thorsson, V, Bass, AJ, and Laird, PW. "Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas." Cancer Cell 33, no. 4 (April 2, 2018): 721-735.e8. Full Text
  - Taylor, AM, Shih, J, Ha, G, Gao, GF, Zhang, X, Berger, AC, Schumacher, SE, Wang, C, Hu, H, Liu, J, Lazar, AJ, Cancer Genome Atlas Research Network, , Cherniack, AD, Beroukhim, R, and Meyerson, M. "Genomic and Functional Approaches to Understanding Cancer Aneuploidy." Cancer Cell 33, no. 4 (April 2, 2018): 676-689.e3. Full Text
  - Wang, Z, Yang, B, Zhang, M, Guo, W, Wu, Z, Wang, Y, Jia, L, Li, S, Cancer Genome Atlas Research Network, , Xie, W, and Yang, D. "lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer." Cancer Cell 33, no. 4 (April 2, 2018): 706-720.e9. Full Text
  - Bailey, MH, Tokheim, C, Porta-Pardo, E, Sengupta, S, Bertrand, D, Weerasinghe, A, Colaprico, A, Wendl, MC, Kim, J, Reardon, B, Ng, PK-S, Jeong, KJ, Cao, S, Wang, Z, Gao, J, Gao, Q, Wang, F, Liu, EM, Mularoni, L, Rubio-Perez, C, Nagarajan, N, Cortés-Ciriano, I, Zhou, DC, Liang, W-W, Hess, JM, Yellapantula, VD, Tamborero, D, Gonzalez-Perez, A, Suphavilai, C, Ko, JY, Khurana, E, Park, PJ, Van Allen, EM, Liang, H, MC3 Working Group, , Cancer Genome Atlas Research Network, , Lawrence, MS, Godzik, A, Lopez-Bigas, N, Stuart, J, Wheeler, D, Getz, G, Chen, K, Lazar, AJ, Mills, GB, Karchin, R, and Ding, L. "Comprehensive Characterization of Cancer Driver Genes and Mutations." Cell 173, no. 2 (April 2018): 371-385.e18. Full Text
  - Campbell, JD, Yau, C, Bowlby, R, Liu, Y, Brennan, K, Fan, H, Taylor, AM, Wang, C, Walter, V, Akbani, R, Byers, LA, Creighton, CJ, Coarfa, C, Shih, J, Cherniack, AD, Gevaert, O, Prunello, M, Shen, H, Anur, P, Chen, J, Cheng, H, Hayes, DN, Bullman, S, Pedamallu, CS, Ojesina, AI, Sadeghi, S, Mungall, KL, Robertson, AG, Benz, C, Schultz, A, Kanchi, RS, Gay, CM, Hegde, A, Diao, L, Wang, J, Ma, W, Sumazin, P, Chiu, H-S, Chen, T-W, Gunaratne, P, Donehower, L, Rader, JS, Zuna, R, Al-Ahmadie, H, Lazar, AJ, Flores, ER, Tsai, KY, Zhou, JH, Rustgi, AK, Drill, E, Shen, R, Wong, CK, Cancer Genome Atlas Research Network, , Stuart, JM, Laird, PW, Hoadley, KA, Weinstein, JN, Peto, M, Pickering, CR, Chen, Z, and Van Waes, C. "Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas." Cell Reports 23, no. 1 (April 2018): 194-212.e6. Full Text
  - Chen, H, Li, C, Peng, X, Zhou, Z, Weinstein, JN, Cancer Genome Atlas Research Network, , and Liang, H. "A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples." Cell 173, no. 2 (April 2018): 386-399.e12. Full Text
  - Chiu, H-S, Somvanshi, S, Patel, E, Chen, T-W, Singh, VP, Zorman, B, Patil, SL, Pan, Y, Chatterjee, SS, Cancer Genome Atlas Research Network, , Sood, AK, Gunaratne, PH, and Sumazin, P. "Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context." Cell Reports 23, no. 1 (April 2018): 297-312.e12. Full Text
  - Ding, L, Bailey, MH, Porta-Pardo, E, Thorsson, V, Colaprico, A, Bertrand, D, Gibbs, DL, Weerasinghe, A, Huang, K-L, Tokheim, C, Cortés-Ciriano, I, Jayasinghe, R, Chen, F, Yu, L, Sun, S, Olsen, C, Kim, J, Taylor, AM, Cherniack, AD, Akbani, R, Suphavilai, C, Nagarajan, N, Stuart, JM, Mills, GB, Wyczalkowski, MA, Vincent, BG, Hutter, CM, Zenklusen, JC, Hoadley, KA, Wendl, MC, Shmulevich, L, Lazar, AJ, Wheeler, DA, Getz, G, and Cancer Genome Atlas Research Network, . "Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics." Cell 173, no. 2 (April 2018): 305-320.e10. Full Text
  - Gao, Q, Liang, W-W, Foltz, SM, Mutharasu, G, Jayasinghe, RG, Cao, S, Liao, W-W, Reynolds, SM, Wyczalkowski, MA, Yao, L, Yu, L, Sun, SQ, Fusion Analysis Working Group, , Cancer Genome Atlas Research Network, , Chen, K, Lazar, AJ, Fields, RC, Wendl, MC, Van Tine, BA, Vij, R, Chen, F, Nykter, M, Shmulevich, I, and Ding, L. "Driver Fusions and Their Implications in the Development and Treatment of Human Cancers." Cell Reports 23, no. 1 (April 2018): 227-238.e3. Full Text
  - Ge, Z, Leighton, JS, Wang, Y, Peng, X, Chen, Z, Chen, H, Sun, Y, Yao, F, Li, J, Zhang, H, Liu, J, Shriver, CD, Hu, H, Cancer Genome Atlas Research Network, , Piwnica-Worms, H, Ma, L, and Liang, H. "Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types." Cell Reports 23, no. 1 (April 2018): 213-226.e3. Full Text
  - Hoadley, KA, Yau, C, Hinoue, T, Wolf, DM, Lazar, AJ, Drill, E, Shen, R, Taylor, AM, Cherniack, AD, Thorsson, V, Akbani, R, Bowlby, R, Wong, CK, Wiznerowicz, M, Sanchez-Vega, F, Robertson, AG, Schneider, BG, Lawrence, MS, Noushmehr, H, Malta, TM, Cancer Genome Atlas Network, , Stuart, JM, Benz, CC, and Laird, PW. "Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer." Cell 173, no. 2 (April 2018): 291-304.e6. Full Text
  - Huang, K-L, Mashl, RJ, Wu, Y, Ritter, DI, Wang, J, Oh, C, Paczkowska, M, Reynolds, S, Wyczalkowski, MA, Oak, N, Scott, AD, Krassowski, M, Cherniack, AD, Houlahan, KE, Jayasinghe, R, Wang, L-B, Zhou, DC, Liu, D, Cao, S, Kim, YW, Koire, A, McMichael, JF, Hucthagowder, V, Kim, T-B, Hahn, A, Wang, C, McLellan, MD, Al-Mulla, F, Johnson, KJ, Cancer Genome Atlas Research Network, , Lichtarge, O, Boutros, PC, Raphael, B, Lazar, AJ, Zhang, W, Wendl, MC, Govindan, R, Jain, S, Wheeler, D, Kulkarni, S, Dipersio, JF, Reimand, J, Meric-Bernstam, F, Chen, K, Shmulevich, I, Plon, SE, Chen, F, and Ding, L. "Pathogenic Germline Variants in 10,389 Adult Cancers." Cell 173, no. 2 (April 2018): 355-370.e14. Full Text
  - Jayasinghe, RG, Cao, S, Gao, Q, Wendl, MC, Vo, NS, Reynolds, SM, Zhao, Y, Climente-González, H, Chai, S, Wang, F, Varghese, R, Huang, M, Liang, W-W, Wyczalkowski, MA, Sengupta, S, Li, Z, Payne, SH, Fenyö, D, Miner, JH, Walter, MJ, Cancer Genome Atlas Research Network, , Vincent, B, Eyras, E, Chen, K, Shmulevich, I, Chen, F, and Ding, L. "Systematic Analysis of Splice-Site-Creating Mutations in Cancer." Cell Reports 23, no. 1 (April 2018): 270-281.e3. Full Text
  - Knijnenburg, TA, Wang, L, Zimmermann, MT, Chambwe, N, Gao, GF, Cherniack, AD, Fan, H, Shen, H, Way, GP, Greene, CS, Liu, Y, Akbani, R, Feng, B, Donehower, LA, Miller, C, Shen, Y, Karimi, M, Chen, H, Kim, P, Jia, P, Shinbrot, E, Zhang, S, Liu, J, Hu, H, Bailey, MH, Yau, C, Wolf, D, Zhao, Z, Weinstein, JN, Li, L, Ding, L, Mills, GB, Laird, PW, Wheeler, DA, Shmulevich, I, Cancer Genome Atlas Research Network, , Monnat, RJ, Xiao, Y, and Wang, C. "Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas." Cell Reports 23, no. 1 (April 2018): 239-254.e6. Full Text
  - Liu, J, Lichtenberg, T, Hoadley, KA, Poisson, LM, Lazar, AJ, Cherniack, AD, Kovatich, AJ, Benz, CC, Levine, DA, Lee, AV, Omberg, L, Wolf, DM, Shriver, CD, Thorsson, V, Cancer Genome Atlas Research Network, , and Hu, H. "An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics." Cell 173, no. 2 (April 2018): 400-416.e11. Full Text
  - Malta, TM, Sokolov, A, Gentles, AJ, Burzykowski, T, Poisson, L, Weinstein, JN, Kamińska, B, Huelsken, J, Omberg, L, Gevaert, O, Colaprico, A, Czerwińska, P, Mazurek, S, Mishra, L, Heyn, H, Krasnitz, A, Godwin, AK, Lazar, AJ, Cancer Genome Atlas Research Network, , Stuart, JM, Hoadley, KA, Laird, PW, Noushmehr, H, and Wiznerowicz, M. "Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation." Cell 173, no. 2 (April 2018): 338-354.e15. Full Text
  - Peng, X, Chen, Z, Farshidfar, F, Xu, X, Lorenzi, PL, Wang, Y, Cheng, F, Tan, L, Mojumdar, K, Du, D, Ge, Z, Li, J, Thomas, GV, Birsoy, K, Liu, L, Zhang, H, Zhao, Z, Marchand, C, Weinstein, JN, Cancer Genome Atlas Research Network, , Bathe, OF, and Liang, H. "Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers." Cell Reports 23, no. 1 (April 2018): 255-269.e4. Full Text
  - Ricketts, CJ, De Cubas, AA, Fan, H, Smith, CC, Lang, M, Reznik, E, Bowlby, R, Gibb, EA, Akbani, R, Beroukhim, R, Bottaro, DP, Choueiri, TK, Gibbs, RA, Godwin, AK, Haake, S, Hakimi, AA, Henske, EP, Hsieh, JJ, Ho, TH, Kanchi, RS, Krishnan, B, Kwiatkowski, DJ, Lui, W, Merino, MJ, Mills, GB, Myers, J, Nickerson, ML, Reuter, VE, Schmidt, LS, Shelley, CS, Shen, H, Shuch, B, Signoretti, S, Srinivasan, R, Tamboli, P, Thomas, G, Vincent, BG, Vocke, CD, Wheeler, DA, Yang, L, Kim, WY, Robertson, AG, Cancer Genome Atlas Research Network, , Spellman, PT, Rathmell, WK, and Linehan, WM. "The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma." Cell Reports 23, no. 1 (April 2018): 313-326.e5. Full Text
  - Saltz, J, Gupta, R, Hou, L, Kurc, T, Singh, P, Nguyen, V, Samaras, D, Shroyer, KR, Zhao, T, Batiste, R, Van Arnam, J, Cancer Genome Atlas Research Network, , Shmulevich, I, Rao, AUK, Lazar, AJ, Sharma, A, and Thorsson, V. "Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images." Cell Reports 23, no. 1 (April 2018): 181-193.e7. Full Text
  - Sanchez-Vega, F, Mina, M, Armenia, J, Chatila, WK, Luna, A, La, KC, Dimitriadoy, S, Liu, DL, Kantheti, HS, Saghafinia, S, Chakravarty, D, Daian, F, Gao, Q, Bailey, MH, Liang, W-W, Foltz, SM, Shmulevich, I, Ding, L, Heins, Z, Ochoa, A, Gross, B, Gao, J, Zhang, H, Kundra, R, Kandoth, C, Bahceci, I, Dervishi, L, Dogrusoz, U, Zhou, W, Shen, H, Laird, PW, Way, GP, Greene, CS, Liang, H, Xiao, Y, Wang, C, Iavarone, A, Berger, AH, Bivona, TG, Lazar, AJ, Hammer, GD, Giordano, T, Kwong, LN, McArthur, G, Huang, C, Tward, AD, Frederick, MJ, McCormick, F, Meyerson, M, Cancer Genome Atlas Research Network, , Van Allen, EM, Cherniack, AD, Ciriello, G, Sander, C, and Schultz, N. "Oncogenic Signaling Pathways in The Cancer Genome Atlas." Cell 173, no. 2 (April 2018): 321-337.e10. Full Text
  - Seiler, M, Peng, S, Agrawal, AA, Palacino, J, Teng, T, Zhu, P, Smith, PG, Cancer Genome Atlas Research Network, , Buonamici, S, and Yu, L. "Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types." Cell Reports 23, no. 1 (April 2018): 282-296.e4. Full Text
  - Way, GP, Sanchez-Vega, F, La, K, Armenia, J, Chatila, WK, Luna, A, Sander, C, Cherniack, AD, Mina, M, Ciriello, G, Schultz, N, Cancer Genome Atlas Research Network, , Sanchez, Y, and Greene, CS. "Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas." Cell Reports 23, no. 1 (April 2018): 172-180.e3. Full Text
  - Ellrott, K, Bailey, MH, Saksena, G, Covington, KR, Kandoth, C, Stewart, C, Hess, J, Ma, S, Chiotti, KE, McLellan, M, Sofia, HJ, Hutter, C, Getz, G, Wheeler, D, Ding, L, MC3 Working Group, , and Cancer Genome Atlas Research Network, . "Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines." Cell Systems 6, no. 3 (March 2018): 271-281.e7. Full Text
  - Schaub, FX, Dhankani, V, Berger, AC, Trivedi, M, Richardson, AB, Shaw, R, Zhao, W, Zhang, X, Ventura, A, Liu, Y, Ayer, DE, Hurlin, PJ, Cherniack, AD, Eisenman, RN, Bernard, B, Grandori, C, and Cancer Genome Atlas Network, . "Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas." Cell Systems 6, no. 3 (March 2018): 282-300.e2. Full Text
  - Foote, J, Lopez-Acevedo, M, Samsa, G, Lee, PS, Kamal, AH, Alvarez Secord, A, and Havrilesky, LJ. "Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 28, no. 2 (February 2018): 302-307. Full Text
  - Johnson, OK, Berchuck, A, Secord, AA, and Peterson, AC. "Urinary diversion in the genitourinary cancer survivor." Gynecologic Oncology 148, no. 2 (February 2018): 414-421. (Review) Full Text
  - Richardson, DL, Sill, MW, Coleman, RL, Sood, AK, Pearl, ML, Kehoe, SM, Carney, ME, Hanjani, P, Van Le, L, Zhou, XC, Alvarez Secord, A, Gray, HJ, Landrum, LM, Lankes, HA, Hu, W, and Aghajanian, C. "Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial." Jama Oncology 4, no. 2 (February 2018): 196-202. Full Text
  - Dotson, S, Landa, A, Ehrisman, J, and Secord, AA. "Safety and feasibility of contained uterine morcellation in women undergoing laparoscopic hysterectomy." Gynecologic Oncology Research and Practice 5 (January 2018): 8-null. Full Text
  - Berchuck, A, Secord, AA, Moss, HA, and Havrilesky, LJ. "Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35, no. 36 (December 2017): 3999-4002. Full Text
  - Foote, J, Secord, AA, Liang, M, Cohn, DE, Jewell, E, and Havrilesky, LJ. "ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer." Journal of Oncology Practice 13, no. 12 (December 2017): e1030-e1039. Full Text
  - Tanner, E, Puechl, A, Levinson, K, Havrilesky, LJ, Sinno, A, Secord, AA, Fader, AN, and Lee, PS. "Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer." Gynecologic Oncology 147, no. 3 (December 2017): 535-540. Full Text
  - Oliver, KE, Brady, WE, Birrer, M, Gershenson, DM, Fleming, G, Copeland, LJ, Tewari, K, Argenta, PA, Mannel, RS, Secord, AA, Stephan, J-M, Mutch, DG, Stehman, FB, Muggia, FM, Rose, PG, Armstrong, DK, Bookman, MA, Burger, RA, and Farley, JH. "An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience." Gynecologic Oncology 147, no. 2 (November 2017): 243-249. Full Text
  - Phippen, NT, Secord, AA, Wolf, S, Samsa, G, Davidson, B, Abernethy, AP, Cella, D, Havrilesky, LJ, Burger, RA, Monk, BJ, and Leath, CA. "Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study." Gynecologic Oncology 147, no. 1 (October 2017): 98-103. Full Text
  - von Gruenigen, VE, Huang, HQ, Beumer, JH, Lankes, HA, Tew, W, Herzog, T, Hurria, A, Mannel, RS, Rizack, T, Landrum, LM, Rose, PG, Salani, R, Bradley, WH, Rutherford, TJ, Higgins, RV, Secord, AA, and Fleming, G. "Chemotherapy Completion in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer—An NRG Oncology/Gynecologic Oncology Group Study." Obstetrical & Gynecological Survey 72, no. 8 (August 2017): 481-482. Full Text
  - Winder, AD, Maniar, KP, Wei, J-J, Liu, D, Scholtens, DM, Lurain, JR, Schink, JC, Buttin, BM, Filiaci, VL, Lankes, HA, Ramirez, NC, Park, K, Singh, M, Lieberman, RW, Mannel, RS, Powell, MA, Backes, FJ, Mathews, CA, Pearl, ML, Secord, AA, Peace, DJ, Mutch, DG, Creasman, WT, and Kim, JJ. "Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study." Cancer 123, no. 7 (April 2017): 1144-1155. Full Text
  - Pierce, SR, Stine, JE, Gehrig, PA, Havrilesky, LJ, Secord, AA, Nakayama, J, Snavely, AC, Moore, DT, and Kim, KH. "Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma." Gynecologic Oncology 144, no. 3 (March 2017): 531-535. Full Text
  - von Gruenigen, VE, Huang, HQ, Beumer, JH, Lankes, HA, Tew, W, Herzog, T, Hurria, A, Mannel, RS, Rizack, T, Landrum, LM, Rose, PG, Salani, R, Bradley, WH, Rutherford, TJ, Higgins, RV, Secord, AA, and Fleming, G. "Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study." Gynecologic Oncology 144, no. 3 (March 2017): 459-467. Full Text
  - Foote, JR, Lopez-Acevedo, M, Buchanan, AH, Secord, AA, Lee, PS, Fountain, C, Myers, ER, Cohn, DE, Reed, SD, and Havrilesky, LJ. "Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer." Journal of Oncology Practice 13, no. 2 (February 2017): e120-e129. Full Text
  - Foote, JR, Lopez-Acevedo, M, Buchanan, AH, Secord, AA, Lee, PS, Fountain, C, Myers, ER, Cohn, DE, Reed, SD, and Havrilesky, LJ. "Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer." Journal of Oncology Practice 13, no. 2 (February 2017): e120-e129. Full Text
  - Foote, JR, Gaillard, S, Broadwater, G, Sosa, JA, Davidson, B, Adam, MA, Secord, AA, Jones, MB, Chino, J, and Havrilesky, LJ. "Disparities in the surgical staging of high-grade endometrial cancer in the United States." Gynecologic Oncology Research and Practice 4 (January 19, 2017): 1-null. Full Text Open Access Copy
  - Lee, PS, Kempner, S, Miller, M, Dominguez, J, Grotegut, C, Ehrisman, J, Previs, R, Havrilesky, LJ, Broadwater, G, Ellestad, SC, and Secord, AA. "Multidisciplinary approach to manage antenatally suspected placenta percreta: updated algorithm and patient outcomes." Gynecologic Oncology Research and Practice 4 (January 2017): 11-null. Full Text Open Access Copy
  - Garcia-Soto, AE, Java, JJ, Nieves Neira, W, Pearson, JM, Cohn, DE, Lele, SB, Tewari, KS, Walker, JL, Alvarez Secord, A, Armstrong, DK, and Copeland, LJ. "Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study." Gynecologic Oncology 143, no. 3 (December 2016): 484-489. Full Text
  - Dottino, JA, Hasselblad, V, Secord, AA, Myers, ER, Chino, J, and Havrilesky, LJ. "Levonorgestrel Intrauterine Device as an Endometrial Cancer Prevention Strategy in Obese Women: A Cost-Effectiveness Analysis." Obstetrics and Gynecology 128, no. 4 (October 2016): 747-753. Full Text
  - Ehrisman, J, Secord, AA, Berchuck, A, Lee, PS, Di Santo, N, Lopez-Acevedo, M, Broadwater, G, Valea, FA, and Havrilesky, LJ. "Performance of sentinel lymph node biopsy in high-risk endometrial cancer." Gynecologic Oncology Reports 17 (August 2016): 69-71. Full Text
  - Secord, AA, and Havrilesky, LJ. "Is Intraperitoneal Chemotherapy Dead?." Obstetrics and Gynecology 127, no. 6 (June 2016): 983-984. Full Text
  - Davidson, BA, Foote, J, Brower, SL, Tian, C, Havrilesky, LJ, and Secord, AA. "Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis." Gynecologic oncology research and practice 3 (January 2016): 13-. Full Text Open Access Copy
  - Gaillard, SL, Secord, AA, and Monk, B. "The role of immune checkpoint inhibition in the treatment of ovarian cancer." Gynecologic Oncology Research and Practice 3 (January 2016): 11-null. (Review) Full Text
  - Gray, HJ, Benigno, B, Berek, J, Chang, J, Mason, J, Mileshkin, L, Mitchell, P, Moradi, M, Recio, FO, Michener, CM, Secord, AA, Tchabo, NE, Chan, JK, Young, J, Kohrt, H, Gargosky, SE, and Goh, JC. "Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial." Journal for Immunotherapy of Cancer 4 (January 2016): 34-null. Full Text Open Access Copy
  - Secord, AA, Hasselblad, V, Von Gruenigen, VE, Gehrig, PA, Modesitt, SC, Bae-Jump, V, and Havrilesky, LJ. "Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis." Gynecologic Oncology 140, no. 1 (January 2016): 184-190. (Review) Full Text
  - Fox, KA, Shamshirsaz, AA, Carusi, D, Secord, AA, Lee, P, Turan, OM, Huls, C, Abuhamad, A, Simhan, H, Barton, J, Wright, J, Silver, R, and Belfort, MA. "Conservative management of morbidly adherent placenta: expert review." American Journal of Obstetrics and Gynecology 213, no. 6 (December 2015): 755-760. (Review) Full Text
  - Fuh, KC, Secord, AA, Bevis, KS, Huh, W, ElNaggar, A, Blansit, K, Previs, R, Tillmanns, T, Kapp, DS, and Chan, JK. "Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients." Gynecologic Oncology 139, no. 3 (December 2015): 413-418. Full Text
  - Dickson, EL, Vogel, RI, Gehrig, PA, Pierce, S, Havrilesky, L, Secord, AA, Dottino, J, Fader, AN, Ricci, S, and Geller, MA. "A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma." Gynecologic Oncology 139, no. 2 (November 2015): 275-282. Full Text
  - Siamakpour-Reihani, S, Owzar, K, Jiang, C, Turner, T, Deng, Y, Bean, SM, Horton, JK, Berchuck, A, Marks, JR, Dewhirst, MW, and Alvarez Secord, A. "Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma." Gynecologic oncology 139, no. 1 (October 2015): 23-29. Full Text
  - Previs, R, III, LCA, Coleman, RL, Herzog, TJ, Krivak, TC, Brower, SL, Tian, C, and Secord, AA. "Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis." GYNECOLOGIC ONCOLOGY 138, no. 2 (August 2015): 267-271. Full Text Link to Item
  - Previs, R, Leath, CA, Coleman, RL, Herzog, TJ, Krivak, TC, Brower, SL, Tian, C, and Secord, AA. "Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis." Gynecologic Oncology 138, no. 2 (August 2015): 267-271. Full Text
  - Zhang, C, Roque, D, Ehrisman, JA, DiSanto, N, Broadwater, G, Doll, KM, Gehrig, PA, Secord, AA, and Havrilesky, LJ. "Lumbee Native American ancestry and the incidence of aggressive histologic subtypes of endometrial cancer." Gynecologic Oncology Reports 13 (August 2015): 49-52. Full Text
  - Kushnir, CL, Angarita, AM, Havrilesky, LJ, Thompson, S, Spahlinger, D, Sinno, AK, Tanner, EJ, Secord, AA, Roche, KL, Stone, RL, and Fader, AN. "Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)." Gynecologic oncology 137, no. 3 (June 2015): 503-507. Full Text
  - Secord, AA, Coleman, RL, Havrilesky, LJ, Abernethy, AP, Samsa, GP, and Cella, D. "Patient-reported outcomes as end points and outcome indicators in solid tumours." Nature Reviews. Clinical Oncology 12, no. 6 (June 2015): 358-370. (Review) Full Text
  - Teoh, D, Lowery, WJ, Jiang, X, Ehrisman, J, Halvorson, P, Broadwater, G, Bentley, R, Secord, AA, Sobolewski, C, Berchuck, A, Havrilesky, LJ, Valea, FA, and Lee, PS. "Vaginal Cuff Thermal Injury by Mode of Colpotomy at Total Laparoscopic Hysterectomy: A Randomized Clinical Trial." JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY 22, no. 2 (February 2015): 227-233. Full Text Link to Item
  - Cobb, LP, Gaillard, S, Wang, Y, Shih, I-M, and Secord, AA. "Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms." Gynecologic Oncology Research and Practice 2 (January 2015): 1-null. Full Text
  - Siamakpour-Reihani, S, Owzar, K, Jiang, C, Turner, T, Deng, Y, Bean, SM, Horton, JK, Berchuck, A, Marks, JR, Dewhirst, MW, and Secord, AA. "Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma." Gynecologic Oncology 139, no. 1 (2015): 23-29. Full Text
  - Havrilesky, LJ, Alvarez Secord, A, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, SL, Samsa, GP, Cella, D, Weinfurt, KP, Abernethy, AP, and Reed, SD. "Patient preferences in advanced or recurrent ovarian cancer." Cancer 120, no. 23 (December 2014): 3651-3659. Full Text
  - Secord, AA, Nixon, AB, and Hurwitz, HI. "The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer." Gynecologic Oncology 135, no. 2 (November 2014): 349-358. (Review) Full Text
  - Herzog, TJ, Alvarez, RD, Secord, A, Goff, BA, Mannel, RS, Monk, BJ, and Coleman, RL. "SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm." Gynecologic oncology 135, no. 1 (October 2014): 3-7. Full Text
  - Kokosis, G, Schmitz, R, Secord, A, Havrilesky, L, Berchuck, A, Mantyh, C, and Erdmann, D. "Modifizierter doppelt gestielter VRAM-Lappen zur simultanen Rekonstruktion eines Perineum- und posterioren vaginalen Defekts." Der Gynäkologe 47, no. 10 (October 2014): 784-787. Full Text
  - Krivak, TC, Lele, S, Richard, S, Secord, AA, Leath, CA, Brower, SL, Tian, C, and Moore, RG. "A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer." American Journal of Obstetrics and Gynecology 211, no. 1 (July 2014): 68.e1-68.e8. Full Text
  - Lee, PS, and Secord, AA. "Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway." Cancer Treat Rev 40, no. 4 (May 2014): 507-512. (Review) Full Text Link to Item
  - Lee, PS, and Secord, AA. "Targeting molecular pathways in endometrial cancer: A focus on the FGFR pathway." Cancer Treatment Reviews 40, no. 4 (May 1, 2014): 507-512. (Review) Full Text
  - Previs, RA, Kilgore, J, Craven, R, Broadwater, G, Bean, S, Wobker, S, DiFurio, M, Bae-Jump, V, Gehrig, PA, and Secord, AA. "Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 24, no. 4 (May 2014): 670-675. Full Text
  - Zhang, C, Havrilesky, LJ, Broadwater, G, Di Santo, N, Ehrisman, JA, Lee, PS, Berchuck, A, Alvarez Secord, A, Bean, S, Bentley, RC, and Valea, FA. "Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients." Gynecologic oncology 133, no. 2 (May 2014): 211-215. Full Text
  - Ko, EM, Walter, P, Clark, L, Jackson, A, Franasiak, J, Bolac, C, Havrilesky, L, Secord, AA, Moore, DT, Gehrig, PA, and Bae-Jump, VL. "The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance." Gynecologic oncology 133, no. 1 (April 2014): 28-32. Full Text
  - Herzog, TJ, Monk, BJ, Rose, PG, Braly, P, Hines, JF, Bell, MC, Wenham, RM, Secord, AA, Roman, LD, Einstein, MH, Drake, RD, and Childs, BH. "A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube." Gynecologic Oncology 132, no. 3 (March 2014): 517-525. Full Text
  - Previs, RA, Bevis, KS, Huh, W, Tillmanns, T, Perry, L, Moore, K, Chapman, J, McClung, C, Kiet, T, Java, J, Chan, J, and Secord, AA. "A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy." Gynecologic Oncology 132, no. 3 (March 2014): 531-536. Full Text
  - Ko, EM, Walter, P, Jackson, A, Clark, L, Franasiak, J, Bolac, C, Havrilesky, LJ, Secord, AA, Moore, DT, Gehrig, PA, and Bae-Jump, V. "Metformin is associated with improved survival in endometrial cancer." Gynecologic Oncology 132, no. 2 (February 2014): 438-442. Full Text
  - Ko, EM, Walter, P, Jackson, A, Clark, L, Franasiak, J, Bolac, C, Havrilesky, LJ, Secord, AA, Moore, DT, Gehrig, PA, and Bae-Jump, V. "Metformin is associated with improved survival in endometrial cancer." Gynecologic Oncology 132, no. 2 (February 1, 2014): 438-442. Full Text
  - Secord, AA, Teoh, D, Jia, J, Nixon, AB, Grace, L, Adams, DJ, and Murphy, SK. "Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 24, no. 2 (February 2014): 218-225. Full Text
  - "Cystic fibrosis involving the cervix, mimicking a well-differentiated adenocarcinoma: A case report." International Journal of Gynecological Pathology 33, no. 1 (January 1, 2014): 100-104. Full Text
  - Davidson, BA, Rubatt, JM, Corcoran, DL, Teoh, DK, Bernardini, MQ, Grace, LA, Soper, WJ, Berchuck, A, Siamakpour-Reihani, S, Chen, W, Owzar, K, Murphy, SK, and Secord, AA. "Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines." Frontiers in Oncology 4 (January 2014): 163-. Full Text
  - Davidson, BA, and Secord, AA. "Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer." International Journal of Women'S Health 6 (January 2014): 289-300. (Review) Full Text Open Access Copy
  - Havrilesky, LJ, Secord, AA, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, SL, Samsa, GP, Cella, D, Weinfurt, KP, Abernethy, AP, and Reed, SD. "Patient preferences in advanced or recurrent ovarian cancer." Cancer 120, no. 23 (January 1, 2014): 3651-3659. Full Text
  - Herzog, TJ, Alvarez, RD, Secord, A, Goff, BA, Mannel, RS, Monk, BJ, and Coleman, RL. "SGO guidance document for clinical trial designs in ovarian cancer: A changing paradigm." Gynecologic Oncology 135, no. 1 (2014): 3-7. Full Text
  - Herzog, TJ, Monk, BJ, Rose, PG, Braly, P, Hines, JF, Bell, MC, Wenham, RM, Secord, AA, Roman, LD, Einstein, MH, Drake, RD, and Childs, BH. "A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube." Gynecologic Oncology 132, no. 3 (January 1, 2014): 517-525. Full Text
  - Kokosis, G, Schmitz, R, Secord, AA, Havrilesky, LJ, Berchuck, A, Mantyh, CR, and Erdmann, D. "A modified bipedicle VRAM flap for simultaneous reconstruction of a perineal and posterior vaginal defect." Gynakologe 47, no. 10 (January 1, 2014): 784-787. Full Text
  - Krivak, TC, Lele, S, Richard, S, Secord, AA, Leath, CA, Brower, SL, Tian, C, and Moore, RG. "A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer." American Journal of Obstetrics and Gynecology 211, no. 1 (2014): 68.e1-68.e8. Full Text
  - Lee, PS, and Secord, AA. "Targeting molecular pathways in endometrial cancer: A focus on the FGFR pathway." Cancer Treatment Reviews 40, no. 4 (2014): 507-512.
  - Lopez-Acevedo, M, Grace, L, Teoh, D, Whitaker, R, Adams, DJ, Jia, J, Nixon, AB, and Secord, AA. "Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines." Gynecologic oncology research and practice 1 (January 2014): 2-. Full Text Open Access Copy
  - Previs, RA, Bevis, KS, Huh, W, Tillmanns, T, Perry, L, Moore, K, Chapman, J, McClung, C, Kiet, T, Java, J, Chan, J, and Secord, AA. "A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy." Gynecologic Oncology 132, no. 3 (January 1, 2014): 531-536. Full Text
  - Previs, RA, Edwards, JM, Secord, AA, Nucci, MR, Bentley, RC, and Hall, AHS. "Cystic fibrosis involving the cervix, mimicking a well-differentiated adenocarcinoma: a case report." International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists 33, no. 1 (January 2014): 100-104. Full Text
  - Zhang, C, Havrilesky, LJ, Broadwater, G, Di Santo, N, Ehrisman, JA, Lee, PS, Berchuck, A, Alvarez Secord, A, Bean, S, Bentley, RC, and Valea, FA. "Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: A single institution study of 458 patients." Gynecologic Oncology 133, no. 2 (January 1, 2014): 211-215. Full Text
  - Ricci, S, Giuntoli, RL, Eisenhauer, E, Lopez, MA, Krill, L, Tanner, EJ, Gehrig, PA, Havrilesky, LJ, Secord, AA, Levinson, K, Frasure, H, Celano, P, and Fader, AN. "Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?." Gynecologic Oncology 131, no. 3 (December 1, 2013): 629-633. Full Text
  - Ricci, S, Giuntoli, RL, Eisenhauer, E, Lopez, MA, Krill, L, Tanner, EJ, Gehrig, PA, Havrilesky, LJ, Secord, AA, Levinson, K, Frasure, H, Celano, P, and Fader, AN. "Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?." Gynecologic Oncology 131, no. 3 (December 2013): 629-633. Full Text
  - Barnett, JC, Alvarez Secord, A, Cohn, DE, Leath, CA, Myers, ER, and Havrilesky, LJ. "Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer." Cancer 119, no. 20 (October 15, 2013): 3653-3661. Full Text Link to Item
  - Karabudak, AA, Hafner, J, Shetty, V, Chen, S, Secord, AA, Morse, MA, and Philip, R. "Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels." Journal of Cancer Research and Clinical Oncology 139, no. 10 (October 2013): 1757-1770. Full Text
  - Krivak, T, Secord, AA, Richard, S, III, LC, Moore, R, Coleman, R, Fiorica, J, Barter, J, Downey, G, Tian, C, and Lele, S. "A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer." GYNECOLOGIC ONCOLOGY 131, no. 1 (October 2013): 276-276. Full Text Link to Item
  - Lowery, WJ, Lowery, AW, Barnett, JC, Lopez-Acevedo, M, Lee, PS, Secord, AA, and Havrilesky, L. "Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer." Gynecol Oncol 130, no. 3 (September 2013): 426-430. Full Text Link to Item
  - Lopez-Acevedo, M, Havrilesky, LJ, Broadwater, G, Kamal, AH, Abernethy, AP, Berchuck, A, Alvarez Secord, A, Tulsky, JA, Valea, F, and Lee, PS. "Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer." Gynecologic Oncology 130, no. 1 (July 2013): 156-161. Full Text
  - Wenham, RM, Lapolla, J, Lin, H-Y, Apte, SM, Lancaster, JM, Judson, PL, Gonzalez-Bosquet, J, Herschberger, A, Havrilesky, LJ, and Secord, AA. "A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy." Gynecologic Oncology 130, no. 1 (July 2013): 19-24. Full Text
  - Zighelboim, I, Wright, JD, Gao, F, Case, AS, Massad, LS, Mutch, DG, Powell, MA, Thaker, PH, Eisenhauer, EL, Cohn, DE, Valea, FA, Alvarez Secord, A, Lippmann, LT, Dehdashti, F, and Rader, JS. "Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer." Gynecol Oncol 130, no. 1 (July 2013): 64-68. Full Text Link to Item
  - Secord, AA, Barnett, JC, Ledermann, JA, Peterson, BL, Myers, ER, and Havrilesky, LJ. "Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 23, no. 5 (June 2013): 846-852. Full Text
  - Hanna, RK, Poniewierski, MS, Laskey, RA, Lopez, MA, Shafer, A, Van Le, L, Crawford, J, Dale, DC, Gehrig, PA, Secord, AA, Havrilesky, LJ, and Lyman, GH. "Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer." Gynecologic Oncology 129, no. 1 (April 2013): 74-80. Full Text
  - Alvarez Secord, A, Bernardini, MQ, Broadwater, G, Grace, LA, Huang, Z, Baba, T, Kondoh, E, Sfakianos, G, Havrilesky, LJ, and Murphy, SK. "TP53 Status is Associated with Thrombospondin1 Expression In vitro. (Published online)" Front Oncol 3 (2013): 269-. Full Text Link to Item
  - Barnett, JC, Secord, AA, Cohn, DE, II, CAL, Myers, ER, and Havrilesky, LJ. "Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer." Cancer 119, no. 20 (2013): 3653-3661. Full Text
  - Chino, J, and Secord, AA. "Image-guided Brachytherapy for Gynecologic Surgeons." Surgical Oncology Clinics of North America (2013). Full Text
  - Chino, J, and Secord, AA. "Image-guided Brachytherapy for Gynecologic Surgeons." Surgical Oncology Clinics of North America 22, no. 3 (2013): 495-509. Full Text
  - Garg, K, Levine, DA, Olvera, N, Dao, F, Bisogna, M, Secord, AA, Berchuck, A, Cerami, E, Schultz, N, and Soslow, RA. "BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas." The American Journal of Surgical Pathology 37, no. 1 (January 2013): 138-146. Full Text
  - Karabudak, AA, Hafner, J, Shetty, V, Chen, S, Secord, AA, Morse, MA, and Philip, R. "Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels." Journal of Cancer Research and Clinical Oncology 139, no. 10 (2013): 1757-1770. Full Text
  - Lopez-Acevedo, M, Havrilesky, LJ, Broadwater, G, Kamal, AH, Abernethy, AP, Berchuck, A, Secord, AA, Tulsky, JA, Valea, F, and Lee, PS. "Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer." Gynecologic Oncology 130, no. 1 (2013): 156-161. Full Text
  - Lowery, WJ, Lowery, AW, Barnett, JC, Lopez-Acevedo, M, Lee, PS, Secord, AA, and Havrilesky, L. "Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer." Gynecologic Oncology 130, no. 3 (2013): 426-430. Full Text
  - Secord, AA, Geller, MA, Broadwater, G, Holloway, R, Shuler, K, Dao, N-Y, Gehrig, PA, O'Malley, DM, Finkler, N, and Havrilesky, LJ. "A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer." Gynecologic Oncology 128, no. 1 (January 2013): 65-70. Full Text
  - Secord, AA, Geller, MA, Broadwater, G, Holloway, R, Shuler, K, Dao, N-Y, Gehrig, PA, O'Malley, DM, Finkler, N, and Havrilesky, LJ. "A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer." Gynecologic Oncology 128, no. 1 (2013): 65-70. Full Text
  - Secord, AA, and Walsh, CS. "Summary of the 44th Annual Meeting on Women's Cancers." Gynecologic Oncology 129, no. 2 (2013): 273-276. Full Text
  - Turner, T, Secord, AA, Lowery, WJ, Sfakianos, G, and Lee, PS. "Metastatic adenocarcinoma after laparoscopic supracervical hysterectomy with morcellation: A case report." Gynecologic Oncology Case Reports 5 (2013): 19-21. Full Text
  - Wenham, RM, Lapolla, J, Lin, H-Y, Apte, SM, Lancaster, JM, Judson, PL, Gonzalez-Bosquet, J, Herschberger, A, Havrilesky, LJ, and Secord, AA. "A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy." Gynecologic Oncology 130, no. 1 (2013): 19-24. Full Text
  - Zighelboim, I, Wright, JD, Gao, F, Case, AS, Massad, LS, Mutch, DG, Powell, MA, Thaker, PH, Eisenhauer, EL, Cohn, DE, Valea, FA, Secord, AA, Lippmann, LT, Dehdashti, F, and Rader, JS. "Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer." Gynecologic Oncology 130, no. 1 (2013): 64-68. Full Text
  - Lopez-Acevedo, M, Zhang, C, Secord, AA, Lee, PS, Havrilesky, LJ, and Berchuck, A. "Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery." JOURNAL OF CLINICAL ONCOLOGY 30, no. 34 (December 1, 2012). Full Text Link to Item
  - Zhang, C, Secord, AA, Lee, PS, Havrilesky, LJ, and Berchuck, A. "Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, no. 34_suppl (December 2012): 201-.
  - Lowery, WJ, Gehrig, PA, Ko, E, Secord, AA, Chino, J, and Havrilesky, LJ. "Surgical staging for endometrial cancer in the elderly - Is there a role for lymphadenectomy?." Obstetrical and Gynecological Survey 67, no. 11 (November 1, 2012): 702-703. Full Text
  - Cantrell, LA, Havrilesky, L, Moore, DT, O'Malley, D, Liotta, M, Secord, AA, Nagel, CI, Cohn, DE, Fader, AN, Wallace, AH, Rose, P, and Gehrig, PA. "A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma." Gynecologic Oncology 127, no. 1 (October 2012): 22-26. Full Text
  - Secord, AA, Teoh, DK, Barry, WT, Yu, M, Broadwater, G, Havrilesky, LJ, Lee, PS, Berchuck, A, Lancaster, J, and Wenham, RM. "A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 18, no. 19 (October 2012): 5489-5498. Full Text
  - Aghajanian, C, Sill, MW, Secord, AA, Powell, MA, and Steinhoff, M. "Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study." Gynecologic Oncology 126, no. 3 (September 2012): 424-427. Full Text
  - Franasiak, J, Ko, EM, Kidd, J, Secord, AA, Bell, M, Boggess, JF, and Gehrig, PA. "Physical strain and urgent need for ergonomic training among gynecologic oncologists who perform minimally invasive surgery." Gynecol Oncol 126, no. 3 (September 2012): 437-442. Full Text Link to Item
  - Fader, AN, Seamon, LG, Escobar, PF, Frasure, HE, Havrilesky, LA, Zanotti, KM, Secord, AA, Boggess, JF, Cohn, DE, Fowler, JM, Skafianos, G, Rossi, E, and Gehrig, PA. "Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers." Gynecol Oncol 126, no. 2 (August 2012): 180-185. Full Text Link to Item
  - Secord, AA, and Gehrig, PA. "Obesity: Too big a problem to ignore." Gynecol Oncol 126, no. 2 (August 2012): 274-276. Full Text Link to Item
  - Alvarez Secord, A, Berchuck, A, Higgins, RV, Nycum, LR, Kohler, MF, Puls, LE, Holloway, RW, Lewandowski, GS, Valea, FA, and Havrilesky, LJ. "A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer." Cancer 118, no. 13 (July 2012): 3283-3293. Full Text
  - Lowery, WJ, Gehrig, PA, Ko, E, Secord, AA, Chino, J, and Havrilesky, LJ. "Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy?." Gynecol Oncol 126, no. 1 (July 2012): 12-15. Full Text Link to Item
  - Vlahovic, G, Meadows, KL, Uronis, HE, Morse, MA, Blobe, GC, Riedel, RF, Zafar, SY, Alvarez-Secord, A, Gockerman, J, Starodub, AN, Ready, NE, Anderson, EL, Bendell, JC, and Hurwitz, HI. "A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors." Cancer Chemotherapy and Pharmacology 70, no. 1 (July 2012): 95-102. Full Text
  - Laskey, RA, Poniewierski, MS, Lopez, MA, Hanna, RK, Secord, AA, Gehrig, PA, Lyman, GH, and Havrilesky, LJ. "Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer." Gynecol Oncol 125, no. 3 (June 2012): 625-630. Full Text Link to Item
  - Chino, JP, Jones, E, Berchuck, A, Secord, AA, and Havrilesky, LJ. "The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer." Int J Radiat Oncol Biol Phys 82, no. 5 (April 1, 2012): 1872-1879. Full Text Link to Item
  - Berchuck, A, Secord, AA, and Havrilesky, LJ. "Minimally invasive surgery for endometrial cancer: the horse is already out of the barn." J Clin Oncol 30, no. 7 (March 1, 2012): 681-682. Full Text Link to Item
  - Teoh, D, and Secord, AA. "Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 22, no. 3 (March 2012): 348-359. (Review) Full Text
  - Edwards, JM, Lowery, WJ, and Secord, AA. "Quinary debulking for epithelial ovarian cancer." Journal of surgical case reports 2012, no. 7 (January 2012): 7-. Full Text
  - Havrilesky, LJ, Pokrzywinski, R, Revicki, D, Higgins, RV, Nycum, LR, Kohler, MF, Berchuck, A, Myers, ER, and Secord, AA. "Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer." Cancer 118, no. 2 (January 2012): 386-391. Full Text
  - Pokrzywinski, R, Secord, AA, Havrilesky, LJ, Puls, LE, Holloway, RW, Lewandowski, GS, Higgins, RV, Nycum, LR, Kohler, MF, and Revicki, DA. "Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial." Gynecologic Oncology 123, no. 3 (December 2011): 505-510. Full Text
  - Alvarez Secord, A, Darcy, KM, Hutson, A, Huang, Z, Lee, PS, Jewell, EL, Havrilesky, LJ, Markman, M, Muggia, F, and Murphy, SK. "The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study." Gynecologic Oncology 123, no. 2 (November 2011): 314-319. Full Text
  - Convery, PA, Cantrell, LA, Di Santo, N, Broadwater, G, Modesitt, SC, Secord, AA, and Havrilesky, LJ. "Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma." Gynecol Oncol 123, no. 1 (October 2011): 65-70. Full Text Link to Item
  - Teoh, D, Berchuck, A, Alvarez Secord, A, Lee, PS, Lowery, WJ, Sfakianos, GP, Valea, FA, Myers, ER, and Havrilesky, LJ. "Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer." Gynecol Oncol 122, no. 3 (September 2011): 467-472. Full Text Link to Item
  - Barnett, JC, Havrilesky, LJ, Bondurant, AE, Fleming, ND, Lee, PS, Secord, AA, Berchuck, A, and Valea, FA. "Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer." Am J Obstet Gynecol 205, no. 2 (August 2011): 143.e1-143.e6. Full Text Link to Item
  - Morse, MA, Secord, AA, Blackwell, K, Hobeika, AC, Sinnathamby, G, Osada, T, Hafner, J, Philip, M, Clay, TM, Lyerly, HK, and Philip, R. "MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer." Clin Cancer Res 17, no. 10 (May 15, 2011): 3408-3419. Full Text Link to Item
  - Havrilesky, LJ, Hanna, RK, Poniewierski, MS, Laskey, R, Secord, AA, Gehrig, PA, Lopez, MA, Shafer, A, Van Le, L, Dale, DC, Crawford, J, and Lyman, GH. "Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 5084-.
  - Teoh, D, Ayeni, TA, Rubatt, JM, Adams, DJ, Grace, L, Starr, MD, Barry, WT, Berchuck, A, Murphy, SK, and Secord, AA. "Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells." Gynecologic Oncology 121, no. 1 (April 2011): 187-192. Full Text
  - Osborne, RJ, Filiaci, V, Schink, JC, Mannel, RS, Alvarez Secord, A, Kelley, JL, Provencher, D, Scott Miller, D, Covens, AL, and Lage, JM. "Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 7 (March 2011): 825-831. Full Text
  - Sinnathamby, G, Zerfass, J, Hafner, J, Block, P, Nickens, Z, Hobeika, A, Secord, AA, Lyerly, HK, Morse, MA, and Philip, R. "ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers." Clin Exp Immunol 163, no. 3 (March 2011): 324-332. Full Text Link to Item
  - Teoh, D, Won, JS, Eisberg, R, Nolte, K, and Secord, AA. "Severe ulceration over mandibular torus in an ovarian cancer patient receiving bevacizumab therapy." Gynecologic Oncology Case Reports 1, no. 1 (2011): 20-21. Full Text
  - Teoh, DGK, and Secord, AA. "Antiangiogenic therapies in epithelial ovarian cancer." Cancer Control : Journal of the Moffitt Cancer Center 18, no. 1 (January 2011): 31-43. (Review) Full Text
  - Zani, S, Stoecker, M, Cox, MW, Secord, AA, and Blazer, DG. "Recurrent granulosa cell tumor presenting with spontaneous retroperitoneal hemorrhage: A case report." Gynecologic Oncology Case Reports 1, no. 1 (2011): 14-16. Full Text
  - Miller, BE, Blessing, JA, Stehman, FB, Shahin, MS, Yamada, SD, Secord, AA, Warshal, DP, Abulafia, O, Richards, WE, and Van Le, L. "A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study." Gynecologic Oncology 118, no. 2 (August 2010): 139-144. Full Text
  - Bernardini, MQ, Baba, T, Lee, PS, Barnett, JC, Sfakianos, GP, Secord, AA, Murphy, SK, Iversen, E, Marks, JR, and Berchuck, A. "Expression signatures of TP53 mutations in serous ovarian cancers." Bmc Cancer 10 (May 26, 2010): 237-null. Full Text Open Access Copy
  - Zighelboim, I, Wright, JD, Powell, MA, Case, AS, Eisenhauer, EL, Cohn, DE, Valea, FA, Secord, AA, Lippmann, LT, and Rader, JS. "Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer." Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): TPS252-TPS252. Full Text
  - Lee, PS, Teaberry, VS, Bland, AE, Huang, Z, Whitaker, RS, Baba, T, Fujii, S, Secord, AA, Berchuck, A, and Murphy, SK. "Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer." Int J Cancer 126, no. 6 (March 15, 2010): 1378-1389. Full Text Link to Item
  - Rasool, N, Fader, AN, Seamon, L, Neubauer, NL, Shahin, FA, Alexander, HA, Moore, K, Moxley, K, Secord, AA, Kunos, C, Rose, PG, and O'Malley, DM. "Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence." Gynecol Oncol 116, no. 1 (January 2010): 10-14. Full Text Link to Item
  - Jewell, EL, Darcy, KM, Hutson, A, Lee, PS, Havrilesky, LJ, Grace, LA, Berchuck, A, and Secord, AA. "Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study." Gynecologic Oncology 115, no. 3 (December 2009): 424-429. Full Text
  - Fader, AN, Starks, D, Gehrig, PA, Secord, AA, Frasure, HE, O'Malley, DM, Tuller, ER, Rose, PG, Havrilesky, LJ, Moore, KN, Huh, WK, Axtell, AE, Kelley, JL, Zanotti, KM, and UPSC Consortium, . "An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)." Gynecol Oncol 115, no. 2 (November 2009): 244-248. Full Text Link to Item
  - Fiorica, JV, Blessing, JA, Puneky, LV, Secord, AA, Hoffman, JS, Yamada, SD, Buekers, TE, Bell, J, Schilder, JM, and Gynecologic Oncology Group, . "A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study." Gynecol Oncol 115, no. 2 (November 2009): 285-289. Full Text Link to Item
  - Secord, AA, and Neubauer, NL. "In response to "The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma"." Gynecologic Oncology 115, no. 2 (November 1, 2009): 317-null. (Letter) Full Text
  - Lee, PS, Bland, A, Valea, FA, Havrilesky, LJ, Berchuck, A, and Secord, AA. "Robotic-assisted laparoscopic gynecologic procedures in a fellowship training program." Jsls : Journal of the Society of Laparoendoscopic Surgeons 13, no. 4 (October 2009): 467-472. Full Text
  - Sinnathamby, G, Lauer, P, Zerfass, J, Hanson, B, Karabudak, A, Krakover, J, Secord, AA, Clay, TM, Morse, MA, Dubensky, TW, Brockstedt, DG, Philip, R, and Giedlin, M. "Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines." J Immunother 32, no. 8 (October 2009): 856-869. Full Text Link to Item
  - Fleming, ND, Alvarez-Secord, A, Von Gruenigen, V, Miller, MJ, and Abernethy, AP. "Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review." Journal of Pain and Symptom Management 38, no. 3 (September 2009): 341-349. (Review) Full Text
  - Secord, AA, Havrilesky, LJ, O'Malley, DM, Bae-Jump, V, Fleming, ND, Broadwater, G, Cohn, DE, and Gehrig, PA. "A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer." Gynecologic Oncology 114, no. 3 (September 2009): 442-447. Full Text
  - Havrilesky, LJ, Secord, AA, O'Malley, DM, Broadwater, G, Bae-Jump, V, Cohn, DE, and Gehrig, PA. "Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer." Gynecol Oncol 114, no. 2 (August 2009): 279-283. Full Text Link to Item
  - Cantrell, LA, Havrilesky, L, O'Malley, D, Liotta, M, Secord, AA, Nagel, C, Fader, AN, Wallace, A, Rose, P, and Gehrig, PA. "Effect of treatment of patients with early-stage uterine carcinosarcoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009): 5516-.
  - Greer, BE, Koh, W-J, Abu-Rustum, N, Bookman, MA, Bristow, RE, Campos, SM, Cho, KR, Copeland, L, Crispens, MA, Eifel, PJ, Huh, WK, Jaggernauth, W, Kapp, DS, Kavanagh, JJ, III, LJR, Morgan, M, Jr, MRJ, Powell, CB, Remmenga, SW, Reynolds, RK, Secord, AA, Jr, SW, and Teng, N. "Uterine Neoplasms Clinical Practice Guidelines in Oncology." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 7, no. 5 (May 2009): 496-531. Full Text Link to Item
  - Greer, BE, Koh, W-J, Abu-Rustum, N, Bookman, MA, Bristow, RE, Campos, SM, Cho, KR, Copeland, L, Crispens, MA, Eifel, PJ, Huh, WK, Jaggernauth, W, Kapp, DS, Kavanagh, JJ, Lurain, JR, Morgan, M, Morgan, RJ, Powell, CB, Remmenga, SW, Reynolds, RK, Alvarez Secord, A, Small, W, and Teng, N. "Uterine Neoplasms. Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network : Jnccn 7, no. 5 (May 2009): 498-531. (Review) Full Text
  - Alvarez Secord, A, Bae-Jump, V, Havrilesky, LJ, Calingaert, B, Clarke-Pearson, DL, Soper, JT, and Gehrig, PA. "Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 19, no. 3 (April 2009): 447-454. Full Text
  - Berchuck, A, Iversen, ES, Luo, J, Clarke, JP, Horne, H, Levine, DA, Boyd, J, Alonso, MA, Secord, AA, Bernardini, MQ, Barnett, JC, Boren, T, Murphy, SK, Dressman, HK, Marks, JR, and Lancaster, JM. "Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 15, no. 7 (April 2009): 2448-2455. Full Text
  - Fader, AN, Nagel, C, Axtell, AE, Zanotti, KM, Kelley, JL, Moore, KN, Secord, AA, Walsh, CS, Huh, WK, Gehrig, PA, Gibbons, H, Rose, PG, Havrilesky, LJ, Tuller, E, Drake, RD, Bottsford-Miller, J, O'Malley, DM, and UPSC Consortium, . "Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes." Gynecol Oncol 112, no. 3 (March 2009): 558-562. Full Text Link to Item
  - Neubauer, NL, Havrilesky, LJ, Calingaert, B, Bulusu, A, Bernardini, MQ, Fleming, ND, Bland, AE, and Secord, AA. "The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma." Gynecol Oncol 112, no. 3 (March 2009): 511-516. Full Text Link to Item
  - Rubatt, JM, Darcy, KM, Hutson, A, Bean, SM, Havrilesky, LJ, Grace, LA, Berchuck, A, and Secord, AA. "Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study." Gynecol Oncol 112, no. 3 (March 2009): 469-474. Full Text Link to Item
  - Resnick, KE, Alder, H, Secord, AA, Whitaker, R, Richardson, DL, Heaphy, C, Murphy, SK, Baba, T, Croce, C, and Colin, DE. "MiRNA patterns in ovarian cancer cell lines: Correlation with serum studies." GYNECOLOGIC ONCOLOGY 112, no. 2 (February 2009): S115-S116. Link to Item
  - Bland, AE, Calingaert, B, Secord, AA, Lee, PS, Valea, FA, Berchuck, A, Soper, JT, and Havrilesky, L. "Relationship between tamoxifen use and high risk endometrial cancer histologic types." Gynecol Oncol 112, no. 1 (January 2009): 150-154. Full Text Link to Item
  - Sabbatini, P, Sill, MW, O'Malley, D, Adler, L, Secord, AA, and Gynecologic Oncology Group Study, . "A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study." Gynecol Oncol 111, no. 3 (December 2008): 455-460. Full Text Link to Item
  - Havrilesky, LJ, Secord, AA, Darcy, KM, Armstrong, DK, Kulasingam, S, and Gynecologic Oncology Group, . "Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 25 (September 2008): 4144-4150. Full Text
  - Lee, PS, Bakelaar, R, Fitpatrick, CB, Ellestad, SC, Havrilesky, LJ, and Alvarez Secord, A. "Medical and surgical treatment of placenta percreta to optimize bladder preservation." Obstet Gynecol 112, no. 2 Pt 2 (August 2008): 421-424. Full Text Link to Item
  - Bland, AE, Shah, AA, Piscitelli, JT, Bentley, RC, and Secord, AA. "Desmoplastic small round cell tumor masquerading as advanced ovarian cancer." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 18, no. 4 (July 2008): 847-850. Full Text
  - Wright, JD, Secord, AA, Numnum, TM, Rocconi, RP, Powell, MA, Berchuck, A, Alvarez, RD, Gibb, RK, Trinkaus, K, Rader, JS, and Mutch, DG. "A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 18, no. 3 (May 2008): 400-406. Full Text
  - Rubatt, JM, Secord, AA, Iversen, E, Grace, L, Soper, W, and Berchuck, A. "Regulation of angiogenic gene expression in p53 wild type and mutant ovarian cancer cells by hypoxia and radiation." GYNECOLOGIC ONCOLOGY 108, no. 3 (March 2008): S84-S84. Link to Item
  - Secord, AA, Blessing, JA, Armstrong, DK, Rodgers, WH, Miner, Z, Barnes, MN, Lewandowski, G, Mannel, RS, and Gynecologic Oncology Group, . "Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study." Gynecologic Oncology 108, no. 3 (March 2008): 493-499. Full Text
  - Kirkpatrick, JP, Rabbani, ZN, Bentley, RC, Hardee, ME, Karol, S, Meyer, J, Oosterwijk, E, Havrilesky, L, Secord, AA, Vujaskovic, Z, Dewhirst, MW, and Jones, EL. "Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer.(Published online)" Biomark Insights 3 (February 1, 2008): 45-55. Link to Item
  - Greer, BE, Koh, W-J, Abu-Rustum, N, Bookman, MA, Bristow, RE, Campos, S, Cho, KR, Copeland, L, Eifel, P, Huh, WK, Jaggernauth, W, Kapp, DS, Kavanagh, J, Lipscomb, GH, Lurain, JR, Morgan, M, Morgan, RJ, Powell, CB, Remmenga, SW, Reynolds, RK, Secord, AA, Small, W, Teng, N, and National Comprehensive Cancer Network, . "Cervical cancer." J Natl Compr Canc Netw 6, no. 1 (January 2008): 14-36. Link to Item
  - Jewell, EL, Kulasingam, S, Myers, ER, Alvarez Secord, A, and Havrilesky, LJ. "Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis." Gynecol Oncol 107, no. 3 (December 2007): 532-540. Full Text Link to Item
  - Alvarez Secord, A, Havrilesky, LJ, Bae-Jump, V, Chin, J, Calingaert, B, Bland, A, Rutledge, TL, Berchuck, A, Clarke-Pearson, DL, and Gehrig, PA. "The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer." Gynecol Oncol 107, no. 2 (November 2007): 285-291. Full Text Link to Item
  - Havrilesky, LJ, Secord, AA, Kulasingam, S, and Myers, E. "Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis." Gynecol Oncol 107, no. 2 (November 2007): 211-218. Full Text Link to Item
  - Rankins, NC, Secord, AA, Jewell, E, Havrilesky, LJ, Soper, JT, and Myers, E. "Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer." Gynecol Oncol 106, no. 2 (August 2007): 388-393. Full Text Link to Item
  - Huh, WK, Straughn, JM, Mariani, A, Podratz, KC, Havrilesky, LJ, Alvarez-Secord, A, Gold, MA, McMeekin, DS, Modesitt, S, Cooper, AL, Powell, MA, Mutch, DG, Nag, S, Alvarez, RD, and Cohn, DE. "Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 17, no. 4 (July 2007): 886-889. Full Text
  - Mutch, DG, Orlando, M, Goss, T, Teneriello, MG, Gordon, AN, McMeekin, SD, Wang, Y, Scribner, DR, Marciniack, M, Naumann, RW, and Secord, AA. "Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 19 (July 2007): 2811-2818. Full Text
  - Secord, AA, Darcy, KM, Hutson, A, Lee, PS, Havrilesky, LJ, Grace, LA, Berchuck, A, and Gynecologic Oncology Group study, . "Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study." Gynecol Oncol 106, no. 1 (July 2007): 221-232. Full Text Link to Item
  - Havrilesky, LJ, Secord, AA, Bae-Jump, V, Ayeni, T, Calingaert, B, Clarke-Pearson, DL, Berchuck, A, and Gehrig, PA. "Outcomes in surgical stage I uterine papillary serous carcinoma." Gynecol Oncol 105, no. 3 (June 2007): 677-682. Full Text Link to Item
  - Alvarez Secord, A, Gehrig, PA, Havrilesky, LJ, Bae-Jump, V, Chin, J, Calingaert, B, Bland, A, Rutledge, T, Berchuck, A, and Clarke-Pearson, DL. "The role of multimodality adjuvant chemotherapy and radiation in women with advanced-stage endometrial cancer." GYNECOLOGIC ONCOLOGY 104, no. 3 (March 2007): S6-S6. Link to Item
  - Havrilesky, LJ, Cragun, JM, Calingaert, B, Alvarez Secord, A, Valea, FA, Clarke-Pearson, DL, Berchuck, A, and Soper, JT. "The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer." Gynecol Oncol 104, no. 2 (February 2007): 401-405. Full Text Link to Item
  - Secord, AA, Havrilesky, LJ, Carney, ME, Soper, JT, Clarke-Pearson, DL, Rodriguez, GC, and Berchuck, A. "Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer." Int J Clin Oncol 12, no. 1 (February 2007): 31-36. Full Text Link to Item
  - Soper, JT, Secord, AA, Havrilesky, LJ, Berchuck, A, and Clarke-Pearson, DL. "Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity." Int J Gynecol Cancer 17, no. 1 (January 2007): 298-303. Full Text Link to Item
  - Secord, AA, and Berchuck, A. "Targeted bio weapons in the war against gynecologic cancers." Contemporary Ob/Gyn 51, no. 10 (October 1, 2006): 48-54. (Review)
  - Lutman, CV, Havrilesky, LJ, Cragun, JM, Secord, AA, Calingaert, B, Berchuck, A, Clarke-Pearson, DL, and Soper, JT. "Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology." Gynecol Oncol 102, no. 1 (July 2006): 92-97. Full Text Link to Item
  - Gynecologic Oncology Group, , Secord, AA, Lee, PS, Darcy, KM, Havrilesky, LJ, Grace, LA, Marks, JR, and Berchuck, A. "Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study." Gynecologic Oncology 101, no. 3 (June 2006): 390-397. Full Text
  - Jewell, E, Secord, AA, Brotherton, T, and Berchuck, A. "Use of trastuzumab in the treatment of metastatic endometrial cancer." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 16, no. 3 (May 2006): 1370-1373. Full Text
  - Jones, E, Alvarez Secord, A, Prosnitz, LR, Samulski, TV, Oleson, JR, Berchuck, A, Clarke-Pearson, D, Soper, J, Dewhirst, MW, and Vujaskovic, Z. "Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma." Int J Hyperthermia 22, no. 2 (March 2006): 161-172. Full Text Link to Item
  - Havrilesky, LJ, Cragun, JM, Calingaert, B, Synan, I, Secord, AA, Soper, JT, Clarke-Pearson, DL, and Berchuck, A. "Resection of lymph node metastases influences survival in stage IIIC endometrial cancer." Gynecologic Oncology 99, no. 3 (December 2005): 689-695. Full Text
  - Alvarez Secord, A, Jones, EL, Hahn, CA, Petros, WP, Yu, D, Havrilesky, LJ, Soper, JT, Berchuck, A, Spasojevic, I, Clarke-Pearson, DL, Prosnitz, LR, and Dewhirst, MW. "Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer." International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 21, no. 4 (June 2005): 333-347. Full Text
  - Cragun, JM, Havrilesky, LJ, Calingaert, B, Synan, I, Secord, AA, Soper, JT, Clarke-Pearson, DL, and Berchuck, A. "Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23, no. 16 (June 2005): 3668-3675. Full Text
  - Hahn, CA, Jones, EL, Blivin, JL, Sanders, LL, Yu, D, Dewhirst, MW, Secord, AA, and Prosnitz, LR. "Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin." Int J Hyperthermia 21, no. 4 (June 2005): 349-357. Full Text Link to Item
  - Soper, JT, Havrilesky, LJ, Secord, AA, Berchuck, A, and Clarke-Pearson, DL. "Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery." Int J Gynecol Cancer 15, no. 3 (May 2005): 542-548. Full Text Link to Item
  - Soper, JT, Secord, AA, Havrilesky, LJ, Berchuck, A, and Clarke-Pearson, DL. "Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity." Gynecol Oncol 97, no. 2 (May 2005): 596-601. Full Text Link to Item
  - Ferrero, S, Ragni, N, and Secord, AA. "Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer [2] (multiple letters)." Gynecologic Oncology 96, no. 1 (2005): 265-266. Full Text
  - Secord, AA. "Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer - Reply." GYNECOLOGIC ONCOLOGY 96, no. 1 (January 2005): 265-266. Full Text Link to Item
  - Alvarez Secord, A, Sayer, R, Snyder, SA, Broadwater, G, Rodriguez, GC, Berchuck, A, and Blackwell, K. "The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer." Gynecologic Oncology 94, no. 1 (July 2004): 74-79. Full Text
  - Berchuck, A, Secord, AA, Havrilesky, LJ, Wenham, R, Soper, JT, and Clarke-Pearson, DL. "Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004): 5152-.
  - Moller, KA, Gehrig, PA, Van Le, L, Secord, AA, and Schorge, J. "The role of optimal debulking in advanced stage serous carcinoma of the uterus." Gynecol Oncol 94, no. 1 (July 2004): 170-174. Full Text Link to Item
  - Secord, AA, Jones, E, Hahn, CA, Havrilesky, LJ, Soper, JT, Berchuck, A, Clarke-Pearson, DL, Prosnitz, LR, and Dewhirst, MW. "Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004): 5089-.
  - Havrilesky, LJ, Leath, CA, Huh, W, Calingaert, B, Bentley, RC, Soper, JT, and Alvarez Secord, A. "Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer." Gynecol Oncol 93, no. 2 (May 2004): 429-434. Full Text Link to Item
  - Berchuck, A, Alvarez, AA, and Stout, JE. "Abdominal pain and bloating in two 20-something patients." Contemporary Ob/Gyn 48, no. 1 (December 1, 2003): 51-58.
  - Roth, TM, Secord, AA, Havrilesky, LJ, Jones, E, and Clarke-Pearson, DL. "High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease." Gynecol Oncol 91, no. 1 (October 2003): 258-260. Link to Item
  - Alvarez, AA, and Clarke-Pearson, DL. "Platinum-resistant and refractory ovarian cancer: Second-line treatment options." American Journal of Cancer 2, no. 1 (September 8, 2003): 1-13. (Review) Full Text
  - Jones, EL, Samulski, TV, Dewhirst, MW, Alvarez-Secord, A, Berchuck, A, Clarke-Pearson, D, Havrilesky, LJ, Soper, J, and Prosnitz, LR. "A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma." Cancer 98, no. 2 (July 15, 2003): 277-282. Full Text Link to Item
  - Havrilesky, LJ, Wong, TZ, Secord, AA, Berchuck, A, Clarke-Pearson, DL, and Jones, EL. "The role of PET scanning in the detection of recurrent cervical cancer." Gynecologic Oncology 90, no. 1 (July 2003): 186-190. Full Text
  - Havrilesky, LJ, Alvarez, AA, Sayer, RA, Lancaster, JM, Soper, JT, Berchuck, A, Clarke-Pearson, DL, Rodriguez, GC, and Carney, ME. "Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer." Gynecologic Oncology 88, no. 1 (January 2003): 51-57. Full Text
  - Havrilesky, LJ, Alvarez, AA, Whitaker, RS, Marks, JR, and Berchuck, A. "Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations." Gynecologic oncology 83, no. 3 (December 2001): 491-500. Full Text
  - Alvarez, AA, Axelrod, JR, Whitaker, RS, Isner, PD, Bentley, RC, Dodge, RK, and Rodriguez, GC. "Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients." Gynecol Oncol 82, no. 2 (August 2001): 273-278. Full Text Link to Item
  - Stout, JE, Woods, CW, Alvarez, AA, Berchuck, A, and Dukes Hamilton, C. "Mycobacterium bovis peritonitis mimicking ovarian cancer in a young woman." Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America 33, no. 4 (August 2001): E14-E16. Full Text
  - Alvarez, AA, Lambers, AR, Lancaster, JM, Maxwell, GL, Ali, S, Gumbs, C, Berchuck, A, and Futreal, PA. "Allele loss on chromosome 1p36 in epithelial ovarian cancers." Gynecologic oncology 82, no. 1 (July 2001): 94-98. Full Text
  - Alvarez, AA, Maxwell, GL, and Rodriguez, GC. "Vacuum-assisted closure for cutaneous gastrointestinal fistula management." Gynecologic oncology 80, no. 3 (March 2001): 413-416. Full Text
  - Maxwell, GL, Risinger, JI, Alvarez, AA, Barrett, JC, and Berchuck, A. "Favorable survival associated with microsatellite instability in endometrioid endometrial cancers." Obstet Gynecol 97, no. 3 (March 2001): 417-422. Link to Item
  - Alvarez, AA, Moore, WF, Robboy, SJ, Bentley, RC, Gumbs, C, Futreal, PA, and Berchuck, A. "K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary." Gynecol Oncol 80, no. 2 (February 2001): 201-206. Full Text Link to Item
  - Maxwell, GL, Risinger, JI, Hayes, KA, Alvarez, AA, Dodge, RK, Barrett, JC, and Berchuck, A. "Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers." Clinical cancer research : an official journal of the American Association for Cancer Research 6, no. 8 (August 2000): 2999-3005.
  - Kearney, P, Secord, A, and Zhang, H. "InVEST: interactive and visual edge selection tool for constructing evolutionary trees." Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing (January 2000): 242-253.
  - Berchuck, A, Alvarez, A, and Futreal, PA. "Prognosis of BRCA1 and 2-associated ovarian cancers." Cme Journal of Gynecologic Oncology 4, no. 1 (December 1, 1999): 108-111. (Review)
  - Alvarez, AA, Krigman, HR, Whitaker, RS, Dodge, RK, and Rodriguez, GC. "The prognostic significance of angiogenesis in epithelial ovarian carcinoma." Clinical cancer research : an official journal of the American Association for Cancer Research 5, no. 3 (March 1999): 587-591.
  - Maxwell, , Risinger, , Shaw, , Alvarez, , Barrett, , Futreal, , and Berchuck, . "Mutations in the PTEN tumor suppressor gene in cervical carcinomas." International Journal of Gynecological Cancer 8, no. 6 (November 1998): 489-493. Full Text
- Book Sections
  - Secord, AA, and Siamakpour-Reihani, S. "Angiogenesis." In Translational Advances in Gynecologic Cancers, 79-109. February 22, 2017. Full Text
  - Romano-Fitzgerald, S, De Meritens, AB, Secord, AA, and Kohn, EC. "Invasion, metastasis, and angiogenesis." In Principles and Practice of Gynecologic Oncology: Sixth Edition, 72-88. May 8, 2013.
- Conference Papers
  - Buechel, M, Enserro, D, Burger, RA, Brady, MF, Wade, K, Secord, AA, Nixon, AB, Mirniaharikandehei, S, Liu, H, Zheng, B, Gray, H, Tewari, KS, O'Malley, DM, Mannel, RS, Moore, KN, and Birrer, MJ. "Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis." : American Society of Clinical Oncology (ASCO), May 20, 2018. Full Text
  - Moore, KN, Secord, AA, Geller, MA, Miller, DS, Cloven, NG, and Fleming, GF. "QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received >= 3 prior chemotherapy regimens." : AMER SOC CLINICAL ONCOLOGY, May 20, 2018. Full Text Link to Item
  - Salinaro, J, Ehrisman, J, Secord, AA, and Davidson, BA. "Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced ovarian cancer." : AMER SOC CLINICAL ONCOLOGY, May 20, 2018. Full Text Link to Item
  - Santin, AD, Fader, A, Roque, DM, Eric, S, Buza, N, Pei, H, Abdelghany, O, Chambers, SK, Secord, AA, Havrilesky, L, O'Malley, DM, Backes, F, Nevadunsky, N, Edraki, B, Pikaart, D, Lowery, W, ElSahwi, K, Celano, P, Bellone, S, Azodi, M, Litkouhi, B, Elena, R, Silasi, DA, and Schwartz, P. "Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002)." : LIPPINCOTT WILLIAMS & WILKINS, November 1, 2017. Link to Item
  - Duska, LR, Brown, J, Jelovac, D, Moore, KN, McGuire, WP, Darus, C, Barroilhet, LM, and Secord, AA. "A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemictabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma." : American Society of Clinical Oncology (ASCO), May 20, 2017. Full Text
  - Foote, J, Havrilesky, LJ, Jewell, EL, Gamble, C, Ehrisman, J, Broadwater, G, Coleman, RL, Cohn, DE, and Secord, AA. "Management of platinum-sensitive recurrent ovarian cancer (PSROC) in the era of biologics: Can ASCO's net health benefits (NHB) inform our decisions?." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 2, 2017 - June 6, 2017.: AMER SOC CLINICAL ONCOLOGY, May 20, 2017. Full Text Link to Item
  - Gaillard, S, Dumbauld, C, Bilewski, A, Ehrisman, JA, Secord, AA, Havrilesky, LJ, Berchuck, A, Weinhold, K, Chan, C, and Yi, J. "Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8(+) T cells in ovarian cancer." May 20, 2017. Full Text Link to Item
  - Davidson, BA, Squatrito, R, Duska, LR, Havrilesky, LJ, Schwager, N, McCollum, M, Arapovic, S, and Secord, AA. "Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma." May 20, 2016. Full Text Link to Item
  - Foote, J, Liang, M, Secord, AA, Cohn, DE, and Havrilesky, LJ. "Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum sensitive ovarian cancer." May 20, 2016. Full Text Link to Item
  - Matulonis, UA, Oza, AM, Secord, AA, Roman, LD, Blagden, SP, Banerjee, SN, Elkas, JC, Nemunaitis, JJ, Ghamande, SA, Fleming, GF, Markham, MJ, Hirte, HW, Provencher, DM, Basu, B, Kristeleit, RS, Naim, S, Hao, Y, Keer, HN, Azab, M, and Matei, D. "Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 3, 2016 - June 7, 2016.: AMER SOC CLINICAL ONCOLOGY, May 20, 2016. Full Text Link to Item
  - Secord, AA, Tritchler, D, Liu, Y, Starr, MD, Brady, JC, Lankes, HA, Hurwitz, H, Mannel, RS, Tewari, KS, O'Malley, DM, Gray, HJ, Bakkum-Gamez, JN, Fujiwara, K, Boente, M, Deng, W, Burger, RA, Birrer, MJ, and Nixon, AB. "Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218." : American Society of Clinical Oncology (ASCO), May 20, 2016. Full Text
  - Ehrisman, JA, Abbott, S, Harmon, Z, Secord, AA, Berchuck, A, Lee, PS, Valea, FA, Broadwater, G, Li, X, Havrilesky, LJ, and Hall, A. "Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-Grade Endometrial Cancer." February 2016. Link to Item
  - Aghajanian, C, Filiaci, VL, Dizon, DS, Carlson, J, Powell, MA, Secord, AA, Tewari, KS, Bender, D, O'Malley, DM, Stuckey, A, Rotmensch, J, Levine, DA, Lankes, HA, and Moore, KN. "A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P." May 20, 2015. Link to Item
  - Davidson, BA, Mannschreck, DB, Broadwater, G, Lopez-Acevedo, M, Lee, PS, Havrilesky, LJ, Valea, FA, Berchuck, A, and Secord, AA. "Findings at laparoscopy, not debulking status, are associated with survival in advanced stage ovarian cancer after neoadjuvant chemotherapy." : Elsevier BV, April 2015. Full Text
  - Ehrisman, JA, Secord, AA, Berchuck, A, Lee, PS, Di Santo, N, Valea, FA, and Havrilesky, LJ. "Sentinel lymph node mapping in women with high risk histology endometrial cancer." : Elsevier BV, April 2015. Full Text
  - Fuh, KC, Secord, AA, Bevis, KS, Huh, WK, Blansit, K, Rosenfeld, E, Hu, L, Previs, RA, Gardner, AB, Kapp, DS, and Chan, JK. "Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy?." : Elsevier BV, April 2015. Full Text
  - Lopez-Acevedo, M, Buchanan, AH, Secord, AA, Lee, PS, Fountain, C, Myers, ER, Cohn, DE, Reed, SD, and Havrilesky, LJ. "Cost comparison among different genetic testing strategies in women with epithelial ovarian cancer." : Elsevier BV, April 2015. Full Text
  - Nakayama, J, Saks, E, Pelkofski, E, Edwards, J, Stine, JE, Secord, AA, Gehrig, PA, and Duska, L. "Laparoscopy compared to laparotomy in the management of granulosa cell tumors of the ovary." : Elsevier BV, April 2015. Full Text
  - Teoh, D, Lowery, WJ, Jiang, X, Ehrisman, J, Halvorson, P, Broadwater, G, Bentley, R, Secord, AA, Sobolewski, C, Berchuck, A, Havrilesky, LJ, Valea, FA, and Lee, PS. "Vaginal cuff thermal injury by mode of colpotomy at total laparoscopic hysterectomy: a randomized clinical trial." February 2015. Full Text
  - Fleming, G, Ghamande, S, Lin, Y, Secord, AA, Nemunaitis, J, Markham, M-J, Nephew, K, Fang, F, Gupta, S, Naim, S, Choy, G, Jueliger, S, Taverna, P, Hao, Y, Keer, H, Azab, M, and Matei, D. "Abstract 2320: Clinical epigenetic resensitization of platinum-resistant, recurrent ovarian cancer patients with SGI-110, a novel, second-generation, subcutaneously administered hypomethylating agent (HMA)." October 1, 2014. Full Text
  - Havrilesky, LJ, Secord, AA, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, S, Cella, D, Weinfurt, K, Abernethy, AP, and Reed, SD. "Relative influence of factors determining a woman’s preference for treatment options in ovarian cancer." : American Society of Clinical Oncology (ASCO), May 20, 2014. Full Text
  - Nakayama, J, Edwards, J, Stine, JE, Pelkofski, E, Gehrlg, PA, Secord, AA, and Duska, LR. "Laparoscopy compared to laparotomy in the management of granulosa cell tumors of the ovary." 50th Annual Meeting of the American-Society-of-Clinical-Oncology. Chicago, IL. May 30, 2014 - June 3, 2014.: AMER SOC CLINICAL ONCOLOGY, May 20, 2014. Full Text Link to Item
  - Roque, DR, Pierce, S, Doll, KM, Davidson, B, Jackson, AL, Ko, EM, Moore, DT, Gehrig, PA, Secord, AA, Havrilesky, LJ, and Bae-Jump, VL. "Endometrial cancer outcomes in hypertensive women treated with beta-blocker." : American Society of Clinical Oncology (ASCO), May 20, 2014. Full Text
  - Tew, WP, Sill, M, McMeekin, DS, Secord, AA, Bonebrake, AJ, Schilder, J, Stuckey, A, Rice, L, Tewari, KS, and Aghajanian, C. "A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC)." : American Society of Clinical Oncology (ASCO), May 20, 2014. Full Text
  - Havrilesky, LJ, Secord, AA, Ehrisman, J, Berchuck, A, Valea, FA, Lee, PS, Cella, D, Weinfurt, K, Abernethy, AP, and Reed, SD. "Relative Influence of Factors Determining a Woman’s Preference for Treatment Options in Ovarian Cancer: A Discrete Choice Experiment." : Elsevier BV, May 2014. Full Text
  - Ko, EM, Walter, P, Clark, LH, Jackson, AL, Franasiak, J, Havrilesky, LJ, Secord, AA, Moore, DT, Gehrig, PA, and Bae-Jump, VL. "The impact of diabetes and obesity on endometrial cancer outcomes." May 20, 2013. Link to Item
  - Stine, JE, Pierce, S, Gehrig, PA, Nakayama, J, Havrilesky, LJ, Secord, AA, Chiu, WK, Moore, DT, and Kim, KH. "Recurrence rates in patients with uterine papillary serous cancer with and without breast cancer." May 20, 2013. Link to Item
  - Siamakpour- Reihani, S, Jiang, C, Turner, T, Owzar, K, Berchuck, A, Dewhirst, M, and Alvarez Secord, A. "Abstract 330A: Differential expression of angiogenic genes in invasive high grade serous ovarian carcinomas." : American Association for Cancer Research (AACR), April 15, 2013. Full Text
  - Zighelboim, I, Wright, JD, Gao, F, Case, AS, Massad, LS, Mutch, DG, Powell, MA, Thaker, PH, Eisenhauer, EL, Cohn, DE, Valea, FA, Secord, AA, Lippmann, LT, and Rader, JS. "Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer." May 20, 2012. Link to Item
  - Havrilesky, LJ, Hanna, RK, Poniewierski, MS, Laskey, R, Secord, AA, Gehrig, PA, Lopez, MA, Shafer, A, Van Le, L, Dale, DC, Crawford, J, and Lyman, GH. "Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer." May 20, 2011. Full Text
  - Gray, HJ, Secord, AA, Anderson, ML, DelPriore, G, Tchabo, NE, and Berek, JS. "A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission." May 20, 2010. Full Text
  - Cantrell, LA, Havrilesky, L, O'Malley, D, Liotta, M, Secord, AA, Nagel, C, Fader, AN, Wallace, A, Rose, P, and Gehrig, PA. "Effect of treatment of patients with early-stage uterine carcinosarcoma." May 20, 2009. Link to Item
  - O'Malley, DM, Nagel, C, Cantrell, LA, Havrilesky, L, Liotta, M, Secord, AA, Nickles, A, Cohn, DE, Wallace, A, Rose, P, and Gehrig, P. "Improved outcomes in advanced stage uterine carcinosarcoma (mixed mullerian tumor [MMT])." May 20, 2009. Link to Item
  - Fader, AN, Starks, D, Rose, PG, Tuller, ER, Gibbons, H, Gehrig, PA, Huh, WK, Havrilesky, LJ, Moore, KN, Axtell, AE, Secord, AA, Kelley, JL, O'Malley, DM, Walsh, C, Drake, RD, Bottsford-Miller, J, and Zanotti, KM. "Early-stage uterine papillary serous carcinoma (UPSC): percentage UPSC, lymphvascular invasion and tumor size are not independent predictors of recurrence." February 2009. Link to Item
  - Havrilesky, LJ, Secord, AA, O'Malley, DM, Bae-Jump, V, Broadwater, G, Tatagari, J, Hamamci, N, and Gehrig, PA. "Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer." February 2009. Link to Item
  - Secord, AA, Havrilesky, LJ, O'Malley, DM, Bae-Jump, V, Fleming, ND, Broadwater, G, Cohn, DE, and Gehrig, PA. "A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer." February 2009. Link to Item
  - Secord, AA, Neubauer, N, Havrilesky, LJ, Calingaert, B, Bernardini, M, Bland, A, and Fleming, N. "The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma." February 2009. Link to Item
  - Shafer, A, Ayeni, TA, Deal, AM, Secord, AA, Soper, JT, Havrilesky, LJ, Van Le, L, and Gehrig, PA. "Improved survival with consolidation chemotherapy after adjuvant paclitaxel and carboplatin in advanced epithelial ovarian cancer." February 2009. Link to Item
  - Lee, PS, Teaberry, V, Bland, AE, Huang, Z, Secord, AA, Berchuck, A, and Murphy, SK. "MAL, a gene associated with survival in epithelial ovarian cancer, is epigenetically regulated." March 2008. Link to Item
  - Rubatt, JM, Darcy, KM, Hutson, A, Bean, SM, Havrilesky, LJ, Lee, PS, Grace, LA, Berchuck, A, and Secord, AA. "Prognostic relevance of microvessel density in previously untreated, advanced-stage epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study." March 2008. Link to Item
  - Shafer, A, Rubatt, JM, Ayeni, T, Deal, AM, Secord, AA, Soper, JT, Havrilesky, LJ, Van Le, L, and Gehring, PA. "Surgical cytoreduction and dose intensity of adjuvant paclitaxel and carboplatin chemotherapy in advanced epithelial ovarian cancer." March 2008. Link to Item
  - Berchuck, A, Lancaster, JM, Iversen, ES, Luo, J, Levine, DA, Boyd, J, Secord, AA, Marks, JR, Nevins, JR, and Dressman, H. "Most early-stage serous ovarian cancers have gene expression profiles predictive of long-term survival." March 2007. Link to Item
  - Secord, AA, Blessing, JA, Armstrong, D, III, BMN, Lewandowski, G, and Mannel, RS. "Phase II study of cetuximab in combination with carboplatin in patients with relapsed platinum-sensitive ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study." March 2007. Link to Item
  - Jones, EL, Havrilesky, LJ, Secord, AA, Clarke-Pearson, DL, Soper, JT, Valea, F, Coleman, RE, and Wong, TZ. "68." : Elsevier BV, November 2006. Full Text
  - Rabbani, ZN, Kirkpatrick, JP, Salahuddin, FK, Bentley, RC, Secord, AA, Greenberg, CS, Havrilesky, LJ, Vujaskovic, Z, Jones, E, and Dewhirst, MW. "1066." : Elsevier BV, November 2006. Full Text
  - Secord, AA, Havrilesky, LJ, Higgins, RV, Nycum, LR, Kohler, MF, Puls, LE, Holloway, R, Soper, JT, Valea, FA, and Berchuck, A. "A comparison of combination docetaxel/carboplatin versus sequential docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer." June 20, 2006. Link to Item
  - Mutch, D, Orlando, M, Teneriello, T, Gordon, A, McMeekin, S, Goss, T, Scribner, D, Naumann, R, Secord, AA, and Wang, Y. "Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct)." October 2005. Link to Item
  - Berchuck, A, Secord, AA, Havrilesky, LJ, Wenham, R, Soper, JT, and Clarke-Pearson, DL. "Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer." July 15, 2004. Link to Item
  - Secord, AA, Jones, E, Hahn, CA, Havrilesky, LJ, Soper, JT, Berchuck, A, Clarke-Pearson, DL, and Prosnitz, LR. "Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer." July 15, 2004. Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Grants

Selected Publications

Academic Articles

Book Sections

Conference Papers